Combination of PARP1 and DNA-PK inhibitors has also been shown to decrease cell growth by 20% in vitro and 60% in vivo in HNSCC cell lines compared to monotherapy of either agent (Fok et al., 2019). The gene discussed is PARP1; the disease is head and neck squamous cell carcinoma.